Is there a role for minimal residual disease monitoring in the management of patients with hairy-cell leukaemia?

Br J Haematol. 2018 Oct;183(1):127-129. doi: 10.1111/bjh.14900. Epub 2017 Aug 18.

Authors

Valentín Ortiz-Maldonado¹, Neus Villamor^{2

3}, Tycho Baumann^{1

3}, Marta Aymerich^{2

3}, Laura Magnano², Pablo Mozas¹, Alfredo Rivas-Delgado¹, Alejandra Martínez-Trillos^{1

3}, Eva Giné^{1

3}, Elías Campo^{2

3}, Armando López-Guillermo^{1

3}, Julio Delgado^{1

3}

Affiliations

¹ Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain.
² Hematopathology Unit, Hospital Clínic, IDIBAPS, Barcelona, Spain.
³ CIBERONC, ISCIII, MINECO, Spain.

PMID: 28832940
DOI: 10.1111/bjh.14900

No abstract available

Keywords: hairy-cell leukaemia; immunophenotyping; minimal residual disease; purine analogues.

Publication types

Letter

MeSH terms

Adult
Aged
Cladribine / therapeutic use
Disease Management
Female
Humans
Immunophenotyping / methods
Leukemia, Hairy Cell / pathology*
Male
Middle Aged
Neoplasm, Residual* / diagnosis
Pentostatin / therapeutic use
Purines / therapeutic use
Rituximab / therapeutic use

Substances

Purines
Pentostatin
Cladribine
Rituximab